WO1994006476A1 - Procede de traitement de l'inflammation dependante du facteur necrosant des tumeurs malignes (tnf) a l'aide d'antagonistes dudit tnf - Google Patents

Procede de traitement de l'inflammation dependante du facteur necrosant des tumeurs malignes (tnf) a l'aide d'antagonistes dudit tnf Download PDF

Info

Publication number
WO1994006476A1
WO1994006476A1 PCT/US1993/008666 US9308666W WO9406476A1 WO 1994006476 A1 WO1994006476 A1 WO 1994006476A1 US 9308666 W US9308666 W US 9308666W WO 9406476 A1 WO9406476 A1 WO 9406476A1
Authority
WO
WIPO (PCT)
Prior art keywords
tnfr
ser
pro
ala
thr
Prior art date
Application number
PCT/US1993/008666
Other languages
English (en)
Inventor
Craig A. Smith
Cindy A. Jacobs
Original Assignee
Immunex Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25484181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1994006476(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corporation filed Critical Immunex Corporation
Priority to AU49209/93A priority Critical patent/AU670125B2/en
Priority to EP93921562A priority patent/EP0620739A4/en
Priority to JP6508252A priority patent/JPH07504203A/ja
Priority to CA002123593A priority patent/CA2123593C/fr
Priority to KR1019940701636A priority patent/KR100232688B1/ko
Publication of WO1994006476A1 publication Critical patent/WO1994006476A1/fr
Priority to NO941780A priority patent/NO941780L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates generally to cytokine receptors and more specifically to a method of using tumor necrosis factor antagonists to suppress TNF- dependent inflammatory diseases.
  • Tumor necrosis factor- ⁇ also known as cachectin
  • tumor necrosis factor- ⁇ also known as lymphotoxin
  • TNF ⁇ tumor necrosis factor- ⁇
  • lymphotoxin tumor necrosis factor- ⁇
  • TNF proteins initiate their biological effect on cells by binding to specific TNF receptor (TNFR ⁇ proteins expressed on the plasma membrane of a TNF-responsive cell.
  • TNF receptor TNF receptor
  • TNFI TNF receptor
  • Type II TNFR TNFRI and TNFRII each bind to both TNF ⁇ and TNF ⁇ .
  • TNFRI and TNFRII have both been molecularly cloned (Smith et al., Science 248:1019, 1990; Loetscher et al., Cell 67:351, 1990 and Schall et al., Cell 61:361, 1990), permitting recombinant expression and purification of soluble TNFR proteins. Soluble TNF binding proteins from human urine have also been identified
  • TNF antagonists such as soluble TNFR and TNF binding proteins, bind to TNF and prevent TNF from binding to cell membrane bound TNF receptors. Such proteins may therefore be useful to suppress biological activities caused by TNF.
  • TNF antagonists have yet to be identified.
  • the present invention provides a method of using TNF antagonists to suppress TNF-dependent inflammatory diseases. Specifically, the present invention provides a method of treating a human having arthritis comprising the step of administering a TNF antagonist, such as soluble human TNFR, to a human.
  • a TNF antagonist such as soluble human TNFR
  • FIGURE 1 shows the dimeric structure of the recombinant human TNFR/Fc fusion protein.
  • the primary translation product of the plasmid coding for rhu TNFR/Fc is a single molecule of soluble TNFR linked to single chain of Fc derived from human IgGl. Following translation, but prior to secretion, this fusion molecule dimerizes via 3 cysteine residues in the Fc region to form dimeric rhu TNFR/Fc. Boxes denote structural domains of TNFR.
  • FIGURE 2 shows the construction of plasmid pCAVDHFR rhu TNFR/Fc.
  • ADH2 yeast alcohol dehydrogenase gene and regulatory region
  • CMV cytomegalovirus immediate early enhancer
  • TPL adenovirus-2 tripartite leader
  • VA adenovirus-2 virus-associated RNA genes I and II
  • DHFR hamster dihydrofolate reductase gene.
  • FIGURES 3 and 4 are graphs showing the effect of intra-articular administration of recombinant human TNFR/Fc, monomeric TNFR, recombinant murine IL-IR and TNFR monomer combined with rmuIL-lR on antigen-induced arthritis in rats.
  • the data indicate that TNFR/Fc, TNFR monomer, rmu IL-IR and TNFR combined with IL-IR suppress inflammation associated with antigen-induced arthritis.
  • FIGURE 5 shows the effect of intraperitoneal administration of recombinant human TNFR/Fc and PBS (vehicle control) on the development of collagen induced arthritis (CIA) in B10.RIII mice.
  • TNFR Fc significantly delayed the onset of CIA.
  • FIGURE 6 shows the effect of intraperitoneal administration of recombinant human TNFR/Fc and PBS (vehicle control) on the development of collagen induced arthritis (CIA) in DBA/1 mice.
  • TNFR Fc significantly delayed the onset of CIA.
  • FIGURE 7 shows that administration of TNFR Fc in mice reduced the arthritis index and the number of joints showing signs of arthritis.
  • TNF receptor and TNFR refer to proteins having amino acid sequences which are substantially similar to the native mammalian TNF receptor or TNF binding protein amino acid sequences, and which are capable of binding TNF molecules and inhibiting TNF from binding to cell membrane bound TNFR.
  • TNFRI Type I TNFR
  • TNFRII Type II TNFR
  • the mature full-length human TNFRI is a glycoprotein having a molecular weight of about 75-80 kilodaltons (kDa).
  • the mature full-length human TNFRII is a glycoprotein having a molecular weight of about 55-60 kilodaltons (kDa).
  • the preferred TNFRs of the present invention are soluble forms of TNFRI and TNFRII, as well as soluble TNF binding proteins.
  • Soluble TNFR molecules include, for example, analogs or subunits of native proteins having at least 20 amino acids and which exhibit at least some biological activity in common with TNFRI, TNFRII or TNF binding proteins.
  • Soluble TNFR constructs are devoid of a transmembrane region (and are secreted from the cell) but retain the ability to bind TNF.
  • bioequivalent protein and amino acid analogs have an amino acid sequence corresponding to all or part of the extracellular region of a native TNFR, for example, huTNFRI ⁇ 235, huTNFRI ⁇ 185 and huTNFRI ⁇ 163, or amino acid sequences substantially similar to the sequences of amino acids 1-163, amino acids 1-185, or amino acids 1-235 of SEQ ID NO:l, and which are biologically active in that they bind to TNF ligand.
  • Equivalent soluble TNFRs include polypeptides which vary from these sequences by one or more substitutions, deletions, or additions, and which retain the ability to bind TNF or inhibit TNF signal transduction activity via cell surface bound TNF receptor proteins, for example huTNFRI ⁇ x, wherein x is selected from the group consisting of any one of amino acids 163-235 of SEQ ID NO: 1. Analogous deletions may be made to muTNFR. Inhibition of TNF signal transduction activity can be determined by transfecting cells with recombinant TNFR DNAs to obtain recombinant receptor expression. The cells are then contacted with TNF and the resulting metabolic effects examined.
  • the recombinant receptor has signal transduction activity.
  • Exemplary procedures for determining whether a polypeptide has signal transduction activity are disclosed by Idzerda et al., J. Exp. Med. 777:861 (1990); Curtis et al., Proc. Natl. Acad. Sci. USA 86:3045 (1989); Prywes et al., EMBO J. 5:2119 (1986) and Chou et al., J. Biol. Chem. 262:1842 (1987).
  • primary cells or cell lines which express an endogenous TNF receptor and have a detectable biological response to TNF could also be utilized.
  • TNFR TNFR
  • huTNFR ⁇ 235 refers to human TNFR having Asp 235 as the C- terminal amino acid (i.e., a polypeptide having the sequence of amino acids 1-235 of SEQ ID NO:l).
  • TNFR refers genetically to mammalian TNFR.
  • TNFR means all forms of TNFR, including mutants and analogs which possess TNFR biological activity.
  • isolated or purified as used in the context of this specification to define the purity of TNFR protein or protein compositions, means that the protein or protein composition is substantially free of other proteins of natural or endogenous origin and contains less than about 1% by mass of protein contaminants residual of production processes. Such compositions, however, can contain other proteins added as stabilizers, carriers, excipients or co-therapeutics.
  • TNFR is isolated if it is detectable as a single protein band in a polyacrylamide gel by silver staining.
  • Recombinant as used herein, means that a protein is derived from recombinant (e.g., microbial or mammalian) expression systems.
  • Microbial refers to recombinant proteins made in bacterial or fungal (e.g., yeast) expression systems.
  • "recombinant microbial” defines a protein produced in a microbial expression system which is essentially free of native endogenous substances. Protein expressed in most bacterial cultures, e.g., E. coli, will be free of glycan. Protein expressed in yeast may have a glycosylation pattern different from that expressed in mammalian cells.
  • biologically active as used throughout the specification as a characteristic of TNF receptors, means that a particular molecule shares sufficient amino acid sequence similarity with the embodiments of the present invention disclosed herein to be capable of binding detectable quantities of TNF, transmitting a TNF stimulus to a cell, for example, as a component of a hybrid receptor construct, or cross-reacting with anti- TNFR antibodies raised against TNFR from natural (i.e., nonrecombinant) sources.
  • biologically active TNF receptors within the scope of the present invention are capable of binding greater than 0.1 nmoles TNF per nmole receptor, and most preferably, greater than 0.5 nmole TNF per nmole receptor in standard binding assays (see below).
  • the present invention utilizes isolated and purified TNF antagonist polypeptides.
  • the isolated and purified TNF antagonist polypeptides used in this invention are substantially free of other contaminating materials of natural or endogenous origin and contain less than about 1% by mass of protein contaminants residual of production processes.
  • the TNF antagonist polypeptides used in this invention are optibnally without associated native-pattern glycosylation.
  • the TNF antagonists are selected from the group consisting of soluble human TNFRI and TNFR II.
  • pCAV/NOT-TNFR has been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852, USA (Accession No. 68088) under the name pCAV/NOT-TNFR.
  • mammalian TNF receptors are presumably encoded by multi-exon genes.
  • Alternative mRNA constructs which can be attributed to different mRNA splicing events following transcription, and which share large regions of identity or similarity with the cDNAs claimed herein may also be used.
  • mammalian TNFR cDNAs may be isolated by using an appropriate human TNFR DNA sequence as a probe for screening a particular mammalian cDNA library by cross-species hybridization.
  • Mammalian TNFR used in the present invention includes, by way of example, primate, human, murine, canine, feline, bovine, ovine, equine and porcine TNFR.
  • Mammalian TNFRs can be obtained by cross species hybridization, using a single stranded cDNA derived from the human TNFR DNA sequence as a hybridization probe to isolate TNFR cDNAs from mammalian cDNA libraries.
  • TNFR Derivatives of TNFR which may be used in the present invention also include various structural forms of the primary protein which retain biological activity. Due to the presence of ionizable amino and carboxyl groups, for example, a TNFR protein may be in the form of acidic or basic salts, or may be in neutral form. Individual amino acid residues may also be modified by oxidation or reduction.
  • the primary amino acid structure may be modified by forming covalent or aggregative conjugates with other chemical moieties, such as glycosyl groups, lipids, phosphate, acetyl groups and the like, or by creating amino acid sequence mutants. Covalent derivatives are prepared by linking particular functional groups to TNFR amino acid side chains or at the N- or C-termini.
  • TNFR neuropeptide
  • conjugated peptide may be a signal (or leader) polypeptide sequence at the N-terminal region of the protein which co-translationally or post- translationally directs transfer of the protein from its site of synthesis to its site of function inside or outside of the cell membrane or wall (e.g., the yeast oc-factor leader).
  • TNFR protein fusions can comprise peptides added to facilitate purification or identification of TNFR (e.g., poly-His).
  • TNF receptor can also be linked to the peptide Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys (DYKDDDDK) (Hopp et al., Bio/Technology 6:1204,1988.)
  • the latter sequence is highly antigenic and provides an epitope reversibly bound by a specific monoclonal antibody, enabling rapid assay and facile purification of expressed recombinant protein.
  • This sequence is also specifically cleaved by bovine mucosal enterokinase at the residue immediately following the Asp-Lys pairing. Fusion proteins capped with this peptide may also be resistant to intracellular degradation in E. coli.
  • TNFR with or without associated native-pattern glycosylation may also be used.
  • TNFR expressed in yeast or mammalian expression systems e.g., COS-7 cells, may be similar or slightly different in molecular weight and glycosylation pattern than the native molecules, depending upon the expression system.
  • Expression of TNFR DNAs in bacteria such as E. coli provides non-glycosylated molecules.
  • Functional mutant analogs of mammalian TNFR having inactivated N-glycosylation sites can be produced by oligonucleotide synthesis and ligation or by site-specific mutagenesis techniques. These analog proteins can be produced in a homogeneous, reduced- carbohydrate form in good yield using yeast expression systems.
  • N-glycosylation sites in eukaryotic proteins are characterized by the amino acid triplet Asn-Aj-Z, where Ai is any amino acid except Pro, and Z is Ser or Thr.
  • Asn provides a side chain amino group for covalent attachment of carbohydrate.
  • Such a site can be eliminated by substituting another amino acid for Asn or for residue Z, deleting Asn or Z, or inserting a non-Z amino acid between Ai and Z, or an amino acid other than Asn between Asn and A].
  • TNFR derivatives may also be obtained by mutations of TNFR or its subunits.
  • a TNFR mutant as referred to herein, is a polypeptide homologous to TNFR but which has an amino acid sequence different from native TNFR because of a deletion, insertion or substitution.
  • Bioequivalent analogs of TNFR proteins may be constructed by, for example, making various substitutions of residues or sequences or deleting terminal or internal residues or sequences not needed for biological activity.
  • cysteine residues can be deleted (e.g., Cys 178 ) or replaced with other amino acids to prevent formation of unnecessary or incorrect intramolecular disulfide bridges upon renaturation.
  • Other approaches to mutagenesis involve modification of adjacent dibasic amino acid residues to enhance expression in yeast systems in which KEX2 protease activity is present.
  • substitutions should be made conservatively; i.e., the most preferred substitute amino acids are those having physiochemical characteristics resembling those of the residue to be replaced.
  • Substantially similar polypeptide sequences generally comprise a like number of amino acids sequences, although C-terminal truncations for the purpose of constructing soluble TNFRs will contain fewer amino acid sequences.
  • deletions and substitutions will preferably result in homologous or conservatively substituted sequences, meaning that a given residue is replaced by a biologically similar residue.
  • conservative substitutions include substitution of one aliphatic residue for another, such as He, Val, Leu, or Ala for one another, or substitutions of one polar residue for another, such as between Lys and Arg; Glu and Asp; or Gin and Asn.
  • Other such conservative substitutions for example, substitutions of entire regions having similar hydrophobicity characteristics, are well known.
  • particular amino acid differences between human, murine and other mammalian TNFRs is suggestive of additional conservative substitutions that may be made without altering the essential biological characteristics of TNFR.
  • Subunits of TNFR may be constructed by deleting terminal or internal residues or sequences. Particularly preferred sequences include those in which the transmembrane region and intracellular domain of TNFR are deleted or substituted with hydrophilic residues to facilitate secretion of the receptor into the cell culture medium.
  • the resulting protein is referred to as a soluble TNFR molecule which retains its ability to bind TNF.
  • a particularly preferred soluble TNFR construct is TNFRI ⁇ 235 (the sequence of amino acids 1-235 of SEQ ID NO:l), which comprises the entire extracellular region of TNFRI, terminating with Asp 235 immediately adjacent the transmembrane region. Additional amino acids may be deleted from the transmembrane region while retaining TNF binding activity.
  • huTNFRI ⁇ 183 which comprises the sequence of amino acids 1-183 of SEQ ID NO:l
  • TNFRI ⁇ 163 which comprises the sequence of amino acids 1-163 of SEQ ID NO:l
  • TNFRI ⁇ 142 does not retain the ability to bind TNF ligand.
  • Cys 157 and Cys 163 is required for formation of an intramolecular disulfide bridge for the proper folding of TNFRI.
  • Cys 178 which was deleted without any apparent adverse effect on the ability of the soluble TNFRI to bind TNF, does not appear to be essential for proper folding of TNFRI.
  • any deletion C-terminal to Cys 163 would be expected to result in a biologically active soluble TNFRI.
  • the present invention contemplates use of such soluble TNFR constructs corresponding to all or part of the extracellular region of TNFR terminating with any amino acid after Cys 163 .
  • Other C-terminal deletions such as TNFRI ⁇ 157, may be made as a matter of convenience by cutting TNFR cDNA with appropriate restriction enzymes and, if necessary, reconstructing specific sequences with synthetic oligonucleotide linkers. Soluble TNFR with N-terminal deletions may also be used in the present invention.
  • the N- terminus of TNFRI may begin with Leu 1 , Pro 2 or Ala 3 without significantly affecting the ability of TNFRI to effectively act as a TNF antagonist.
  • the resulting soluble TNFR constructs are then inserted and expressed in appropriate expression vectors and assayed for the ability to bind TNF.
  • Mutations in nucleotide sequences constructed for expression of analog TNFR must, of course, preserve the reading frame phase of the coding sequences and preferably will not create complementary regions that could hybridize to produce secondary mRNA structures such as loops or hairpins which would adversely affect translation of the receptor mRNA.
  • a mutation site may be predetermined, it is not necessary that the nature of the mutation per se be predetermined. For example, in order to select for optimum characteristics of mutants at a given site, random mutagenesis may be conducted at the target codon and the expressed TNFR mutants screened for the desired activity.
  • nucleotide sequence which encodes TNFR will be expressed in the final product, for example, nucleotide substitutions may be made to enhance expression, primarily to avoid secondary structure loops in the transcribed mRNA (see EPA 75,444A, incorporated herein by reference), or to provide codons that are more readily translated by the selected host, e.g., the well-known E. coli preference codons for E. coli expression.
  • Mutations can be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes an analog having the desired amino acid insertion, substitution, or deletion.
  • oligonucleotide-directed site-specific mutagenesis procedures can be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required.
  • Exemplary methods of making the alterations set forth above are disclosed by Walder et al. (Gene 42:133, 1986); Bauer et al. (Gene 37:13, 1985); Craik (BioTechniques, January 1985, 12-19); Smith et al. (Genetic Engineering: Principles and Methods, Plenum Press, 1981); and U.S. Patent Nos. 4,518,584 and 4,737,462 disclose suitable techniques, and are incorporated by reference herein.
  • TNFR Both monovalent forms and polyvalent forms of TNFR may also be used in the present invention.
  • Polyvalent forms possess multiple TNFR binding sites for TNF ligand.
  • a bivalent soluble TNFR may consist of two tandem repeats of amino acids 1-235 of SEQ ID NO:l, separated by a linker region.
  • Alternate polyvalent forms may also be constructed, for example, by chemically coupling TNFR to any clinically acceptable carrier molecule, a polymer selected from the group consisting of Ficoll, polyethylene glycol or dextran using conventional coupling techniques.
  • TNFR may be chemically coupled to biotin, and the biotin-TNFR conjugate then allowed to bind to avidin, resulting in tetravalent avidin/biotin/TNFR molecules.
  • TNFR may also be covalently coupled to dinitrophenol (DNP) or trinitrophenol (TNP) and the resulting conjugate precipitated with anti-DNP or anti- TNP-IgM, to form decameric conjugates with a valency of 10 for TNFR binding sites.
  • DNP dinitrophenol
  • TNP trinitrophenol
  • a recombinant chimeric antibody molecule may also be produced having TNFR sequences substituted for the variable domains of either or both of the immunoglobulin molecule heavy and light chains and having unmodified constant region domains.
  • chimeric TNFR/IgGi m ay be produced from two chimeric genes ⁇ a TNFR/human K light chain chimera (TNFR/C K ) and a TNFR/human ⁇ i heavy chain chimera (TNFR/C ⁇ .i).
  • TNFR/C K TNFR/human K light chain chimera
  • TNFR/C ⁇ .i TNFR/human ⁇ i heavy chain chimera
  • the gene products assemble into a single chimeric antibody molecule having TNFR displayed bivalently.
  • Such polyvalent forms of TNFR may have enhanced binding affinity for TNF ligand.
  • a TNFR/Fc fusion protein is disclosed in SEQ ID NO:3 and SEQ ID NO:4. Additional details relating to the construction of such chimeric antibody molecules are disclosed in WO 89/09622 and EP 315062.
  • Recombinant expression vectors are preferably used to amplify or express DNA encoding TNFR to obtain purified TNFR.
  • Recombinant expression vectors are replicable DNA constructs which have synthetic or cDNA-derived DNA fragments encoding mammalian TI "R or bioequivalent analogs operably linked to suitable transcriptional or translational regulatory elements derived from mammalia;; nicrobial, viral or insect genes.
  • a transcriptional unit generally comprises an assemoiy of (1) a genetic element or elements having a regulatory role in gene expression, for example, transcriptional promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription and translation initiation and termination sequences, as described in detail below.
  • Such regulatory elements may include an operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites.
  • the ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants may additionally be incorporated.
  • DNA regions are operably linked when they are functionally related to each other. For example, DNA for a signal peptide (secretory leader) is operably linked to DNA for a polypeptide if it is expressed as a precursor which participates in the secretion of the polypeptide; a promoter is operably linked to a coding sequence if it controls the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation.
  • signal peptide secretory leader
  • a promoter is operably linked to a coding sequence if it controls the transcription of the sequence
  • a ribosome binding site is operably linked to a coding sequence if it is positioned so
  • operably linked means contiguous and, in the case of secretory leaders, contiguous and in reading frame.
  • Structural elements intended for use in yeast expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell.
  • recombinant protein may include an N-terminal methionine residue. This residue may optionally be subsequently cleaved from the expressed recombinant protein to provide a final product.
  • DNA sequences encoding mammalian TNF receptors which are to be expressed in a microorganism will preferably contain no introns that could prematurely terminate transcription of DNA into mRNA; however, premature termination of transcription may be desirable, for example, where it would result in mutants having advantageous C-terminal truncations, for example, deletion of a transmembrane region to yield a soluble receptor not bound to the cell membrane. Due to code degeneracy, there can be considerable variation in nucleotide sequences encoding the same amino acid sequence. Other embodiments include sequences capable of hybridizing to the sequences of the provided cDNA under moderately stringent conditions (50°C, 2x SSC) and other sequences hybridizing or degenerate to those which encode biologically active TNF receptor polypeptides.
  • moderately stringent conditions 50°C, 2x SSC
  • Recombinant TNFR DNA is expressed or amplified in a recombinant expression system comprising a substantially homogeneous monoculture of suitable host microorganisms, for example, bacteria such as E. coli or yeast such as S. cerevisiae, which have stably integrated (by transformation or transfection) a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit as a component of a resident plasmid.
  • suitable host microorganisms for example, bacteria such as E. coli or yeast such as S. cerevisiae, which have stably integrated (by transformation or transfection) a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit as a component of a resident plasmid.
  • suitable host microorganisms for example, bacteria such as E. coli or yeast such as S. cerevisiae, which have stably integrated (by transformation or transfection) a recomb
  • Transformed host cells are cells which have been transformed or transfected with TNFR vectors constructed using recombinant DNA techniques.
  • Transformed host cells ordinarily express TNFR, but host cells transformed for purposes of cloning or amplifying TNFR DNA do not need to express TNFR.
  • Expressed TNFR will be deposited in the cell membrane or secreted into the culture supernatant, depending on the TNFR DNA selected.
  • Suitable host cells for expression of mammalian TNFR include prokaryotes, yeast or higher eukaryotic cells under the control of appropriate promoters. Prokaryotes include gram negative or gram positive organisms, for example E. coli or bacilli. Higher eukaryotic cells include established cell lines of mammalian origin as described below.
  • RNAs derived from the DNA constructs of the present invention are described by Pouwels et al. (Cloning Vectors: A Laboratory Manual, Elsevier, New York, 1985), the relevant disclosure of which is hereby incorporated by reference.
  • Prokaryotic expression hosts may be used for expression of TNFR that do not require extensive proteolytic and disulfide processing.
  • Prokaryotic expression vectors generally comprise one or more phenotypic selectable markers, for example a gene encoding proteins conferring antibiotic resistance or supplying an autotrophic requirement, and an origin of replication recognized by the host to ensure amplification within the host.
  • Suitable prokaryotic hosts for transformation include E. coli, Bacillus subtilis, Salmonella typhimurium, and various species within the genera Pseudomonas, Streptomyces, and Staphyolococcus, although others may also be employed as a matter of choice.
  • Useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017).
  • Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEMl (Promega Biotec, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed.
  • E. coli is typically transformed using derivatives of pBR322, a plasmid derived from an E. coli species (Bolivar et al., Gene 2:95, 1977).
  • pBR322 contains genes for ampicillin and tetracycline resistance and thus provides simple means for identifying transformed cells.
  • Promoters commonly used in recombinant microbial expression vectors include the ⁇ -lactamase (penicillinase) and lactose promoter system (Chang et al., Nature 275:615, 1978; and Goeddel et al., Nature 281:544, 1979), the tryptophan (trp) promoter system (Goeddel et al., Nucl. Acids Res. 8:4051, 1980; and EPA 36,776) and tac promoter (Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, p. 412, 1982).
  • Plasmid vectors available from the American Type Culture Collection which incorporate derivatives of the ⁇ P promoter include plasmid pHUB2, resident in E. coli strain JMB9 (ATCC 37092) and pPLc28, resident in E. coli RR1 (ATCC 53082).
  • Recombinant TNFR proteins may also be expressed in yeast hosts, preferably from the Saccharomyces species, such as S. cerevisiae. Yeast of other genera, such as Pichia or Kluyveromyces may also be employed. Yeast vectors will generally contain an origin of replication from the 2 ⁇ yeast plasmid or an autonomously replicating sequence (ARS), promoter, DNA encoding TNFR, sequences for polyadenylation and transcription termination and a selection gene. Preferably, yeast vectors will include an origin of replication and selectable marker permitting transformation of both yeast and E. coli, e.g., the ampicillin resistance gene of E. coli and S.
  • ARS autonomously replicating sequence
  • TRP1 or URA3 gene which provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, and a promoter derived from a highly expressed yeast gene to induce transcription of a structural sequence downstream.
  • the presence of the TRP1 or URA3 lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan or uracil.
  • Suitable promoter sequences in yeast vectors include the promoters for metallothionein, 3-phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem. 255:2013, 1980) or other glycolytic enzymes (Hess et al., /. Adv.
  • Suitable vectors and promoters for use in yeast expression are further described in R. Hitzeman et al., ⁇ PA 73,657.
  • Preferred yeast vectors can be assembled using DNA sequences from pUC18 for selection and replication in E. coli (Amp r gene and origin of replication) and yeast DNA sequences including a glucose-repressible ADH2 promoter and ⁇ -factor secretion leader.
  • the ADH2 promoter has been described by Russell et al. (J. Biol. Chem. 258:2614, 1982) and Beier et al. (Nature 300:124, 1982).
  • the yeast ⁇ -factor leader which directs secretion of heterologous proteins, can be inserted between the promoter and the structural gene to be expressed. See, e.g., Kurjan et al., Cell 30:933, 1982; and Bitter et al., Proc. Natl.
  • the leader sequence may be modified to contain, near its 3' end, one or more useful restriction sites to facilitate fusion of the leader sequence to foreign genes.
  • Suitable yeast transformation protocols are known to those of skill in the art; an exemplary technique is described by Hinnen et al., Proc. Natl. Acad. Sci.
  • Trp + transformants in a selective medium consisting of 0.67% yeast nitrogen base, 0.5% casamino acids, 2% glucose, 10 ⁇ g/ml adenine and 20 ⁇ g/ml uracil or URA+ tranformants in medium consisting of 0.67% YNB, with amino acids and bases as described by Sherman et al., Laboratory Course Manual for Methods in Yeast Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1986.
  • Host strains transformed by vectors comprising the ADH2 promoter may be grown for expression in a rich medium consisting of 1% yeast extract, 2% peptone, and 1% or 4% glucose supplemented with 80 ⁇ g/ml adenine and 80 ⁇ g/ml uracil. Derepression of the ADH2 promoter occurs upon exhaustion of medium glucose. Crude yeast supernatants are harvested by filtration and held at 4°C prior to further purification.
  • Various mammalian or insect cell culture systems are also advantageously employed to express recombinant protein. Expression of recombinant proteins in mammalian cells is particularly preferred because such proteins are generally correctly folded, appropriately modified and completely functional.
  • mammalian host cell lines include the COS-7 lines of monkey kidney cells, described by Gluzman (Cell 23:115, 1981), and other cell lines capable of expressing an appropriate vector including, for example, L cells, C127, 3T3, Chinese hamster ovary (CHO), HeLa and BHK cell lines.
  • Mammalian expression vectors may comprise non transcribed elements such as an origin of replication, a suitable promoter and enhancer linked to the gene to be expressed, and other 5' or 3' flanking non transcribed sequences, and 5' or 3' nontranslated sequences, such as necessary ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and transcriptional termination sequences.
  • Baculovirus systems for production of heterologous proteins in insect cells are reviewed by Luckow and Summers, Bio/Technology 6:41 (1988).
  • the transcriptional and translational control sequences in expression vectors to be used in transforming vertebrate cells may be provided by viral sources.
  • viral sources for example, commonly used promoters and enhancers are derived from Polyoma, Adenovirus 2, Simian Virus 40 (SV40), and human cytomegalovirus.
  • DNA sequences derived from the SV40 viral genome for example, SV40 origin, early and late promoter, enhancer, splice, and polyadenylation sites may be used to provide the other genetic elements required for expression of a heterologous DNA sequence.
  • the early and late promoters are particularly useful because both re obtained easily from the virus as a fragment which also contains the S V40 viral origin of replication (Fiers et al., Nature 273:113, 1978).
  • Smaller or larger SV40 fragments may also be used, provided the approximately 250 bp sequence extending from the Hind 3 site toward the Bgll site located in the viral origin of replication is included.
  • mammalian genomic TNFR promoter, control and/or signal sequences may be utilized, provided such control sequences are compatible with the host cell chosen. Additional details regarding the use of a mammalian high expression vector to produce a recombinant mammalian TNF receptor are provided in Examples 2 and 7 below. Exemplary vectors can be constructed as disclosed by Okayama and Berg (Mol. Cell. Biol. 5:280, 1983).
  • a useful system for stable high level expression of mammalian receptor cDNAs in C 127 murine mammary epithelial cells can be constructed substantially as described by Cosman et al. (Mol. Immunol. 23:935, 1986).
  • Recombinant expression vectors comprising TNFR cDNAs are stably integrated into a host cell's DNA. Elevated levels of expression product is achieved by selecting for cell lines having amplified numbers of vector DNA.
  • Cell lines having amplified numbers of vector DNA are selected, for example, by transforming a host cell with a vector comprising a DNA sequence which encodes an enzyme which is inhibited by a known drug.
  • the vector may also comprise a DNA sequence which encodes a desired protein.
  • the host cell may be co-transformed with a second vector which comprises the DNA sequence which encodes the desired protein. The transformed or co-transformed host cells are then cultured in increasing concentrations of the known drug, thereby selecting for drug-resistant cells.
  • Such drug-resistant cells survive in increased concentrations of the toxic drug by over-production of the enzyme which is inhibited by the drug, frequently as a result of amplification of the gene encoding the enzyme.
  • drug resistance is caused by an increase in the copy number of the vector DNA encoding the inhibitable enzyme, there is a concomitant co-amplification of the vector DNA encoding the desired protein (TNFR) in the host cell's DNA.
  • a preferred system for such co-amplification uses the gene for dihydrofolate reductase (DHFR), which can be inhibited by the drug methotrexate (MTX).
  • DHFR dihydrofolate reductase
  • MTX drug methotrexate
  • a host cell which lacks an active gene encoding DHFR is either transformed with a vector which comprises DNA sequence encoding DHFR and a desired protein, or is co- transformed with a vector comprising a DNA sequence encoding DHFR and a vector comprising a DNA sequence encoding the desired protein.
  • the transformed or co-transformed host cells are cultured in media containing increasing levels of MTX, and those cells lines which survive are selected.
  • a particularly preferred co-amplification system uses the gene for glutamine synthetase (GS), which is responsible for the synthesis of glutamate and ammonia using the hydrolysis of ATP to ADP and phosphate to drive the reaction.
  • GS is subject to inhibition by a variety of inhibitors, for example methionine sulphoximine (MSX).
  • MSX methionine sulphoximine
  • TNFR can be expressed in high concentrations by co-amplifying cells transformed with a vector comprising the DNA sequence for GS and a desired protein, or co-transformed with a vector comprising a DNA sequence encoding GS and a vector comprising a DNA sequence encoding the desired protein, culturing the host cells in media containing increasing levels of MSX and selecting for surviving cells.
  • the GS co-amplification system, appropriate recombinant expression vectors and cells lines, are described in the following PCT applications: WO 87/04462, WO 89/01036, WO 89/10404 and
  • Recombinant proteins are preferably expressed by co-amplification of DHFR or
  • GS in a mammalian host cell such as Chinese Hamster Ovary (CHO) cells
  • a murine myeloma cell line such as SP2/0-Agl4 or NSO
  • a rat myeloma cell line such as YB2/3.0-Ag20, disclosed in PCT applications
  • pCAV/NOT A preferred eukaryotic vector for expression of TNFR DNA is disclosed below in Example 1.
  • This vector referred to as pCAV/NOT, was derived from the mammalian high expression vector pDC201 and contains regulatory sequences from SV40, adenovirus-2, and human cytomegalovirus.
  • Purified mammalian TNF receptors or analogs are prepared by culturing suitable host/vector systems to express the recombinant translation products of the DNAs of the present invention, which are then purified from culture media or cell extracts.
  • supernatants from systems which secrete recombinant protein into culture media can be first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit.
  • the concentrate can be applied to a suitable purification matrix.
  • a suitable affinity matrix can comprise a TNF or lectin or antibody molecule bound to a suitable support.
  • an anion exchange resin can be employed, for example, a matrix or substrate having pendant diethylaminoethyl (DEAE) groups.
  • the matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification.
  • a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups. Sulfopropyl groups are preferred.
  • RP-HPLC steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify a TNFR composition.
  • hydrophobic RP-HPLC media e.g., silica gel having pendant methyl or other aliphatic groups.
  • Recombinant protein produced in bacterial culture is usually isolated by initial extraction from cell pellets, followed by one or more concentration, salting-out, aqueous ion exchange or size exclusion chromatography steps. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.
  • Microbial cells employed in expression of recombinant mammalian TNFR can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Fermentation of yeast which express mammalian TNFR as a secreted protein greatly simplifies purification. Secreted recombinant protein resulting from a large- scale fermentation can be purified by methods analogous to those disclosed by Urdal et al. (J. Chromatog. 296:111, 1984). This reference describes two sequential, reversed- phase HPLC steps for purification of recombinant human GM-CSF on a preparative HPLC column.
  • Human TNFR synthesized in recombinant culture is characterized by the presence of non-human cell components, including proteins, in amounts and of a character which depend upon the purification steps taken to recover human TNFR from the culture. These components ordinarily will be of yeast, prokaryotic or non-human higher eukaryotic origin and preferably are present in innocuous contaminant quantities, on the order of less than about 1 percent by weight. Further, recombinant cell culture enables the production of TNFR free of proteins which may be normally associated with TNFR as it is found in nature in its species of origin, e.g. in cells, cell exudates or body fluids.
  • the present invention provides methods of suppressing TNF-dependent inflammatory responses in humans comprising administering an effective amount of a TNF antagonist, such as TNFR, and a suitable diluent and carrier.
  • a TNF antagonist such as TNFR
  • a suitable diluent and carrier for therapeutic use, purified soluble TNFR protein is administered to a patient, preferably a human, for treatment of arthritis.
  • soluble TNFR protein compositions can be administered, for example, via intra-articular, intraperitoneal or subcutaneous routes by bolus injection, continuous infusion, sustained release from implants, or other suitable techniques.
  • a soluble TNFR therapeutic agent will be administered in the form of a composition comprising purified protein in conjunction with physiologically acceptable carriers, excipients or diluents.
  • Such carriers will be nontoxic to recipients at the dosages and concentrations employed.
  • the preparation of such compositions entails combining the TNFR with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrins, chelating agents such as EDTA, glutathione and other stabilizers and excipients.
  • buffers such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrins, chelating agents such as EDTA, glutathione and other stabilizers and excipients.
  • Neutral buffered saline or saline mixed with con specific serum albumin are exemplary appropriate diluents.
  • product is formulated as a lyophilizate using appropriate excipient solutions (e.g., sucrose) as diluents.
  • Appropriate dosages can be determined in trials.
  • preservatives may also be added, such as benzyl alcohol.
  • the amount and frequency of administration will depend, of course, on such factors as the nature and severity of the indication being treated, the desired response, the condition of the patient, and so forth.
  • TNF antagonist proteins are administered to a mammal, preferably a human, for the purpose treating TNF-dependent inflammatory diseases, such as arthritis.
  • TNFRI proteins inhibit TNF-dependent arthritic responses.
  • combination therapy using TNFR in combination with IL-IR and/or IL-2R may be preferred in the treatment of TNF-associated clinical indications.
  • soluble human TNFR is preferred.
  • Either Type I IL-IR or Type II IL-IR, or a combination thereof, may be used in accordance with the present invention to treat TNF-dependent inflammatory diseases, such as arthritis.
  • Other types of TNF binding proteins may be similarly used.
  • TNFR is administered in systemic amounts ranging from about 0.1 mg kg/week to about 100 mg/kg/week. In preferred embodiments of the present invention, TNFR is administered in amounts ranging from about 0.5 mg kg/week to about 50 mg/kg/week. For local intra-articular administration, dosages preferably range from about 0.01 mg/kg to about 1.0 mg/kg per injection.
  • the expression vector pCAV/NOT-TNFR (ATCC 68088) containing the TNFR cDNA clone 1 was used to prepare and express a soluble human TNFRI as follows.
  • a cDNA encoding a soluble human TNFRI ⁇ 235 (the primary translation product of which had the sequence of amino acids -22-235 of SEQ ID NO: l) was constructed by excising an 840 bp fragment from pCAV/NOT-TNFR with the restriction enzymes Notl and Pvu2.
  • two oligonucleotides were synthesized and annealed to create the following oligonucleotide linker encoding amino acids corresponding to amino acids 229-235 of SEQ ID NO: 1:
  • This oligonucleotide linker has terminal Pvu2 and Bgl2 restriction sites, regenerates 20 nucleotides of the TNFR, followed by a termination codon (underlined) and a BamHl restriction site (for convenience in isolating the entire soluble TNFR by Notl/BamHl digestion).
  • This oligonucleotide was then ligated with the 840 bp Notl/Pvu2 TNFR insert into Bgl2/Notl cut pCAV/NOT to yield psolhuTNFR ⁇ 235/CAVNOT, which was transfected into COS-7 cells as described above.
  • the host cells expressed a mature a soluble human TNFRI protein having the sequence of amino acids 1-235 which was capable of binding TNF.
  • FIG. 1 A schematic diagram showing the construction of a recombinant soluble human TNFR:Fc expression vector is shown in Figure 1.
  • the rhu TNFR:Fc fusion gene was created by ligating the following fragments into Bluescript®, a commercially available cloning vector (Stratagene):
  • Plasmid pIXY498 is a yeast expression vector containing the Fc fragment of human IgGl (see Figure 2).
  • An oligonucleotide linker to fuse the truncated TNFR with the human IgGl Fc fragment. This linker was created by PCR (polymerase chain reaction) amplification using two primers, one having the sequence CCCCAGCTGAAGGGAGCACTGGCG ACGAGCCCAAATCTTGTGACAAAACTC (nucleotides 833-883 of SEQ ID
  • CGGTACGTGCTGTTGTTACTGC SEQ ID NO:5
  • the template for this reaction was pIXY498.
  • the reaction product was digested with Pvu2 and Styl, and a
  • Plasmid pCA V/NOT/DHFR was derived from plasmid pCAV/NOT by inserting the hamster dihydrofolate reductase DNA sequence (DHFR) into the Hpal site of pCAV/NOT ( Figure 2). This construct was designated plasmid pCAVDHFRhuTNFRFc. The entire coding region sequence was confirmed by DNA sequencing and is depicted in Figure 2.
  • DXB-11 CHO cells deficient in the expression of dihydrofolate reductase were obtained from Dr. Lawren Chasin at Columbia University. A bank of 100 vials of these cells was established, and representative vials were sent to Microbiological Associates for examination via the following procedures:
  • Transfections were performed by mixing pCAVDHFRhuTNFRFc plasmid DNA with LipofectinTM reagent from Gibco BRL. Approximately 10 >g of DNA was added to 10 cm petri dishes containing CHO DXB-11 cells. After the initial transfection, cells were selected for the expression of DHFR by subculturing in selective medium lacking glycine, hypoxanthine and thymidine. The resulting colonies were then transferred to 24 well plates and analyzed for rhu TNFR:Fc expression. The highest expressing cultures were subjected to amplification by exposure to increasing concentrations of methotrexate (MTX).
  • MTX methotrexate
  • Soluble TNF receptor was expressed in Chinese Hamster Ovary (CHO) cells using the glutamine-synthetase (GS) gene amplification system, substantially as described in PCT patent application Nos. WO87/04462 and WO89/01036. Briefly, CHO cells are transfected with an expression vector containing genes for both TNFR and GS. CHO cells are selected for GS gene expression based on the ability of the transfected DNA to confer resistance to low levels of methionine sulphoximine (MSX). GS sequence amplification events in such cells are selected using elevated MSX concentrations. In this way, contiguous TNFR sequences are also amplified and enhanced TNFR expression is achieved.
  • MSX methionine sulphoximine
  • the vector used in the GS expression system was psolTNFR/P6/PSVLGS, which was constructed as follows. First, the vector pSVLGS.l (described in PCT Application Nos. WO87/04462 and WO89/01036, and available from Celltech, Ltd., Berkshire, UK) was cut with the BamHl restriction enzyme and dephosphorylated with calf intestinal alkaline phosphatase (CIAP) to prevent the vector from religating to itself. The BamHl cut pSVLGS.l fragment was then ligated to a 2.4 kb BamHl to Bgl2 fragment of pEE ⁇ hCMV (described in PCT Application No.
  • pSVLGS.l contains the glutamine synthetase selectable marker gene under control of the SV40 later promoter.
  • the BamHl to Bgl2 fragment of pEE ⁇ hCMV contains the human cytomegalovirus major immediate early promoter (hCMV), a polylinker, and the SV40 early polyadenylation signal.
  • the coding sequences for soluble TNFR were added to p6 PSVLGS.l by excising a Notl to BamHl fragment from the expression vector psolTNFR/CAVNOT (made according to Example 3 above), blunt ending with Klenow and ligating with Smal cut dephosphorylated p6/PSVLGS.l, thereby placing the solTNFR coding sequences under the control of the hCMV promoter.
  • psolTNFR/P6/PSVLGS was used to transfect CHO-K1 cells (available from ATCC, Rochville, MD, under accession number CCL 61) as follows.
  • a monolayer of CHO-K1 cells were grown to subconfluency in Minimum Essential Medium (MEM) 10X (Gibco: 330-1581AJ) without glutamine and supplemented with 10% dialysed fetal bovine serum (Gibco: 220-6300AJ), 1 mM sodium pyruvate (Sigma), MEM non- essential amino acids (Gibco: 320-1140AG), 500 ⁇ M asparagine and glutamate (Sigma) and nucleosides (30 ⁇ M adenosine, guanosine, cytidine and uridine and 10 ⁇ M thymidine)(Sigma).
  • MEM Minimum Essential Medium
  • nucleosides 30 ⁇ M adenosine, guanosine, cytidine and ur
  • MSX-resistant cell lines are transfected with psolTNFR/P6/PSVLGS and grown in various concentrations of MSX.
  • approximately lxlO 6 cells are plated in gradually increasing concentrations of 100 uM, 250 uM, 500 uM and 1 mM MSX and incubated for 10-14 days. After 12 days, colonies resistant to the higher levels of MSX appear. The surviving colonies are assayed for TNFR activity.
  • Each of these highly resistant cell lines contains cells which arise from multiple independent amplification events. From these cells lines, one or more of the most highly resistant cells lines are isolated. The amplified cells with high production rates are then cloned by limiting dilution cloning. Mass cell cultures of the transfectants secrete active soluble TNFR.
  • mBSA methylated bovine serum albumin
  • ALA antigen-induced arthritis
  • Administration of rhu TNFR:Fc, TNFR monomer, recombinant murine soluble IL-1 receptor (rm IL-IR) or a combination of TNFR monomer plus rm IL-IR was shown to be effective in suppressing the effects of antigen-induced arthritis in rats.
  • TNFR monomer was produced in CHO cells according to Example 2.
  • the rhu TNFR:Fc used in this experiment was produced in BHK (hamster kidney) cells. This material is similar to the CHO cell-derived TNFR.
  • Figures 3 and 4 demonstrate that treatment with BHK-derived rhu TNFR:Fc at the time of mBSA challenge and for two days following challenge resulted in a reduction of knee-joint swelling in comparison to diluent-treated control rats.
  • a reduction in joint swelling and inflammation was observed in rats treated with 5 or 10 ⁇ g BHK-derived rhu TNFR:Fc or 5 ⁇ g TNFR monomer or 1 ⁇ g of rmuIL-lR. Reduction in joint swelling was even more pronounced when rmuIL-lR and TNFR monomer treatment was combined.
  • Histopathological examination of the joints harvested on day 6 was performed to confirm the degree of swelling. Histopathology scores were derived by evaluating knee joints and scoring their condition as follows: Grade 1, minimal, ⁇ 10% of area affected; Grade 2, moderate, 10-50% of area affected; Grade 3, marked, at least 50%, but less than all, of area affected; Grade 4, maximal, total area severely affected. A variety of lesions/alterations involving five knee joint structures were evaluated: joint capsule, joint space, synovial membrane, articular cartilage, and subchondral bone. Each structural alteration was scored from 1 to 4, and the scores were added and means were calculated. Histopathology results are expressed as the mean score in each treatment group.
  • Table B shows histopathology results, which also indicate that rhu TNFR:Fc, TNFR monomer and rmu IL-IR were effective in reducing the severity of antigen-induced arthritis, and that a combination of rm IL-IR and TNFR monomer was more effective than either receptor alone.
  • BIO.RIII mice previously immunized with porcine type II collagen (CII) in complete Freund's adjuvant consistently develop collagen-induced arthritis (CIA).
  • CII porcine type II collagen
  • BIO.RIII mice were immunized intradermally with 100 ⁇ g porcine type II collagen (CII) in complete Freund's adjuvant to induced arthritic symptoms. Approximately 14-17 days post-immunization, symptoms of clinical arthritis began to appear in the mice, with 90-100% of the mice displaying severe arthritis by day 28.
  • CII porcine type II collagen
  • mice were injected intraperitoneally with TNFR Fc or PBS to determine the effect of soluble TNFR/Fc on CIA. Mice were assessed for symptoms of arthritis at 12 weeks post-immunization .
  • TNFR Fc was administered over the entire period of CIA development. Twelve mice were injected with 10 ⁇ g TNFR/Fc, 3 days per week, from days 0 to 35. Twelve control mice were injected with PBS.
  • Figure 5 shows that
  • TNFR/Fc significantly reduced the incidence of arthritis when compared to controls.
  • mice Upon cessation of treatment with TNFR/Fc, the mice developed arthritis.
  • TNFR/Fc was administered during only the developmental stages of CIA on days -1-17 relative to immunization, as set forth in the following Table C.
  • Days -1 to 17 (alternate days) These data show that TNFR/Fc delayed the onset of arthritis, but that CIA was unaltered in mice receiving 30 ⁇ g TNFR/Fc the day before and 3 days after immunization with type II collagen. Mice given 10 ⁇ g TNFR/Fc, every other day, from day -1 to day 17 displayed a slight decrease in CIA incidence and severity versus controls injected with PBS.
  • TNFR/Fc was administered during only the progressive stages of CIA every other day on days 14-28 post-immunization as set forth in the following Table D.
  • mice were immunized with 100 ⁇ g of CII and then injected intraperitoneally with 50 ⁇ g recombinant soluble human TNFR/Fc in sterile saline from day 21 to day 28.
  • Control mice received sterile saline (vehicle) injections. This treatment period was prior to the development of the clinical signs of CIA, but during the development of DTH responses to type II collagen and rapid IgG anti-CII production.
  • TNFR/Fc significantly reduced the incidence of CIA compared with controls (28% vs. 86%; p ⁇ 0.03), and reduced both arthritis index (a subjective measure of severity) and the number of involved joints.
  • the antibody response to CII was significantly lower immediately post treatment with TNFR/Fc (day 28), but antibody levels were equivalent at the conclusion of the experiment (day 70).
  • TNFR Fc is effective in reducing the incidence of CIA in mice and may therefore be useful in the treatment arthritis.
  • ORGANISM Homo sapiens (G) CELL TYPE: Fibroblast (H) CELL LINE: WI-26 VA4 28
  • ACG TCC ACG TCC CCC ACC CGG AGT ATG GCC CCA GGG GCA GTA CAC TTA 735 Thr Ser Thr Ser Pro Thr Arg Ser Met Ala Pro Gly Ala Val His Leu 180 185 190
  • MOLECULE TYPE protein
  • MOLECULE TYPE DNA (genomic)
  • HYPOTHETICAL NO
  • ANTI-SENSE YES

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Procédé de traitement de maladies inflammatoires dépendantes du TNF chez un mammifère, consistant à administrer un antagoniste du TNF, tel qu'un récepteur de TNF soluble.
PCT/US1993/008666 1992-09-15 1993-09-14 Procede de traitement de l'inflammation dependante du facteur necrosant des tumeurs malignes (tnf) a l'aide d'antagonistes dudit tnf WO1994006476A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU49209/93A AU670125B2 (en) 1992-09-15 1993-09-14 Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
EP93921562A EP0620739A4 (en) 1992-09-15 1993-09-14 Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
JP6508252A JPH07504203A (ja) 1992-09-15 1993-09-14 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法
CA002123593A CA2123593C (fr) 1992-09-15 1993-09-14 Methode de traitement de l'inflammation dependante du tnf a l'aide d'antagonistes du facteur de necrose tumorale
KR1019940701636A KR100232688B1 (ko) 1992-09-15 1993-09-14 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
NO941780A NO941780L (no) 1992-09-15 1994-05-11 Fremgangsmåte for behandling av TNF-avhengig inflammasjon under anvendelse av tumornekrosefaktorantagonister

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94623692A 1992-09-15 1992-09-15
US07/946,236 1992-09-15

Publications (1)

Publication Number Publication Date
WO1994006476A1 true WO1994006476A1 (fr) 1994-03-31

Family

ID=25484181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/008666 WO1994006476A1 (fr) 1992-09-15 1993-09-14 Procede de traitement de l'inflammation dependante du facteur necrosant des tumeurs malignes (tnf) a l'aide d'antagonistes dudit tnf

Country Status (8)

Country Link
EP (1) EP0620739A4 (fr)
JP (1) JPH07504203A (fr)
KR (1) KR100232688B1 (fr)
AU (1) AU670125B2 (fr)
CA (1) CA2123593C (fr)
NO (1) NO941780L (fr)
NZ (1) NZ256293A (fr)
WO (1) WO1994006476A1 (fr)

Cited By (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0670730A1 (fr) * 1992-03-30 1995-09-13 Immunex Corporation Proteines de fusion comprenant un recepteur de facteur de necrose tumorale
WO1996003141A1 (fr) * 1994-07-22 1996-02-08 F. Hoffmann-La Roche Ag Compositions pharmaceutiques comprenant une proteine chimere liant le facteur de necrose tumorale
WO1996023888A1 (fr) * 1995-02-03 1996-08-08 G.D. Searle & Co. NOUVEAUX LIGANDS SE FIXANT A c-MPL
WO1996039488A1 (fr) * 1995-06-06 1996-12-12 Genentech, Inc. Procede de regulation de la sialylation de proteines produites par une culture de cellules de mammiferes
WO1997003686A1 (fr) * 1995-07-14 1997-02-06 Applied Research Systems Recepteur de tnf et hormone steroïdienne en therapie combinee
WO1997041895A2 (fr) * 1996-05-08 1997-11-13 F. Hoffmann-La Roche Ag TRAITEMENT DE L'ASTHME PAR TNFR-Ig
EP0812208A1 (fr) * 1995-03-01 1997-12-17 YEDA RESEARCH AND DEVELOPMENT CO., Ltd. Compositions pharmaceutiques destinees a la liberation regulee de recepteurs solubles
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
WO1998024463A2 (fr) * 1996-12-06 1998-06-11 Amgen Inc. Therapie combinatoire utilisant une proteine de liaison du facteur de necrose tumorale (tnf) dans le traitement de maladies induites par le tnf
WO1998051344A1 (fr) * 1997-05-12 1998-11-19 The Kennedy Institute Of Rheumatology Suppression therapeutique du facteur de necrose tumorale alpha et du facteur de croissance des cellules endotheliales vasculaires
WO1999003999A1 (fr) * 1997-07-17 1999-01-28 The Regents Of The University Of Michigan Procedes et compositions servant a inhiber la reaction proinflammatoire
WO2000025745A2 (fr) * 1998-11-05 2000-05-11 Omeros Medical Systems, Inc. Solution d'irrigation et methode pour l'inhibition de la douleur et de l'inflammation
WO2000040225A2 (fr) * 1998-12-30 2000-07-13 Applied Research Systems Ars Holding N.V. Inhibition de l'activite du tnf
EP1022027A1 (fr) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Antagonistes du TNF (Tumor necrosis factor) et leurs utilisations contre l'endometriose
WO2000059530A1 (fr) * 1999-04-02 2000-10-12 Immunex Corporation Utilisation d'un recepteur du facteur de necrose tumorale soluble dans le traitement de l'insuffisance cardiaque
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
WO2000073481A1 (fr) * 1999-05-28 2000-12-07 Targeted Genetics Corporation Techniques et compositions permettant d'abaisser le niveau de facteur de necrose tumorale (tnf) dans les troubles associes au tnf
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
EP1097165A1 (fr) * 1998-07-13 2001-05-09 Parkash S. Gill Nouveaux inhibiteurs de l'angiogenese et de la croissance tumorale
WO2001038526A1 (fr) * 1999-11-23 2001-05-31 Glaxo Group Limited Récepteur de tnf humain
US6271346B1 (en) 1989-04-21 2001-08-07 Amgen Inc. TNF Receptors, TNF binding proteins and DNAs coding for them
WO2002100330A2 (fr) 2001-06-08 2002-12-19 Abbott Biotechnology Ltd Methodes d'administration d'anticorps anti-tnf$g(a)
US6541620B1 (en) 1989-07-18 2003-04-01 Angen Inc. Nucleic acids encoding TNF inhibitor and method of production
EP1352656A2 (fr) * 1996-12-06 2003-10-15 Amgen Inc. Thérapie combinatoire utilisant une protèine de liaison du facteur de nécrose tumorale (TNF) dans le traitement de maladies induites par le TNF
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
WO2004037205A2 (fr) 2002-10-24 2004-05-06 Abbott Biotechnology Ltd. THERAPIES FAIBLEMENT DOSEES POUR TRAITER DES TROUBLES POUR LESQUELS L'ACTIVITE DES FACTEURS DE NECROSE TUMORALE α EST PREJUDICIABLE
US6733753B2 (en) 1997-02-10 2004-05-11 Amgen Inc. Composition and method for treating inflammatory diseases
WO2004075918A1 (fr) * 2003-02-28 2004-09-10 Ares Trading S.A. Preparations liquides de proteines de liaison au facteur de necrose tumorale
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
WO2005110452A2 (fr) 2004-04-09 2005-11-24 Abbott Biotechnology Ltd. Regime posologique a variables multiples destine a traiter des troubles associes a tnf?
US7012060B1 (en) 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
SG123531A1 (en) * 1998-12-17 2006-07-26 Biogen Idec Inc A method for the high level expression of active lymphotoxin-beta receptor immunoglobulin chimeric proteins and their purification
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
WO2006105344A2 (fr) * 2005-03-31 2006-10-05 Targeted Genetics Corporation Procedes d'abaissement de niveau de facteur tnf dans les troubles associes a ce facteur
US7118863B2 (en) 1999-08-04 2006-10-10 Amgen, Inc. Methods for detecting NTR3 nucleic acids by hybridization
WO2007024705A2 (fr) 2005-08-19 2007-03-01 Abbott Biotechnology Ltd. Procede de traitement de la depression au moyen d'un anticorps anti-tnf-alpha
WO2006053301A3 (fr) * 2004-11-12 2007-04-05 Xencor Inc Variants fc presentant une liaison modifiee au fcrn
US7208577B2 (en) 1995-11-22 2007-04-24 Amgen, Inc. Methods of increasing lean tissue mass using OB protein compositions
US7229962B2 (en) 2001-07-26 2007-06-12 Medexgen Co., Ltd. Tetravalent etanercept
US7238776B2 (en) 1989-04-21 2007-07-03 Amgen Inc. TNF binding proteins
WO2007089303A2 (fr) 2005-11-01 2007-08-09 Abbott Biotechnology Ltd. Méthodes et compositions de diagnostic de la spondylarthrite ankylosante à l'aide de biomarqueurs
US7320796B2 (en) 1999-07-09 2008-01-22 Amgen Inc. Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
WO2008025747A1 (fr) * 2006-08-28 2008-03-06 Ares Trading S.A. Procédé de purification de protéines fc-hybrides
WO2008051306A1 (fr) * 2006-10-20 2008-05-02 Ercole Biotech, Inc. Récepteurs de tnf solubles et leur utilisation pour le traitement de maladies
WO2008054603A2 (fr) 2006-10-02 2008-05-08 Amgen Inc. Protéines de liaison à l'antigène du récepteur a de l'il-17
WO2008063213A2 (fr) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
EP1939300A1 (fr) * 1999-05-28 2008-07-02 Targeted Genetics Corporation Procédés et compositions pour diminuer le niveau de facteur de nécrose de tumeur (TNF) pour des troubles associés au TNF
EP1944322A2 (fr) 2002-07-19 2008-07-16 Abbott Biotechnology Ltd. Traitement des troubles associés au TND alpha
EP1797869A3 (fr) * 1999-07-21 2008-07-23 Omeros Corporation Solutions et procédés pour l'inhibition d'inflammations douloureuses et de détériorations du cartilage
WO2008154543A2 (fr) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Procédés de traitement de l'arthrite idiopathique juvénile
US7544519B2 (en) 1999-08-04 2009-06-09 Amgen Inc. Fhm a novel member of the TNF ligand supergene family: materials and methods for interaction modulators
EP2072527A1 (fr) 2007-12-21 2009-06-24 Altonabiotec AG Procédé et système pour fournir des services de communications sur un terminal mobile, et terminal mobile
WO2010018444A2 (fr) * 2008-08-12 2010-02-18 Avesthagen Limited Vecteur d'expression et son procédé
US7732587B2 (en) 1996-07-09 2010-06-08 Amgen Inc. Nucleic acids encoding truncated soluble tumor necrosis factor
EP2196218A2 (fr) 2002-04-26 2010-06-16 Abbott Biotechnology Ltd Utilisation d'anticorps anti-TNFalpha et d'un autre médicament
WO2010077722A1 (fr) 2008-12-30 2010-07-08 Centocor Ortho Biotech Inc. Marqueurs sériques prédisant la réponse clinique à des anticorps anti-tnf chez les patients souffrant de spondylarthrite ankylosante
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
US7838489B2 (en) 1996-08-01 2010-11-23 The Mathilda And Terence Kennedy Institute Of Rheumatology Trust Methods of treating rheumatoid arthritis with p75 TNF-alpha receptor and methotrexate
EP2305712A1 (fr) 1996-02-09 2011-04-06 Abbott Biotechnology Ltd Anticorps humains se fixant au facteur necrosant des tumeurs de type alpha
WO2011046958A1 (fr) 2009-10-12 2011-04-21 Amgen Inc. Utilisation des proteines se liant a un antigene du recepteur a de l'il-17
WO2011075578A1 (fr) 2009-12-16 2011-06-23 Philip Bosch Procédés de traitement de la cystite interstitielle
US7972599B2 (en) 2006-03-20 2011-07-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Immunomodulation of inflammatory conditions utilizing Follistatin-like protein-1 and agents that bind thereto
WO2011097301A2 (fr) 2010-02-02 2011-08-11 Abbott Biotechnology Ltd. Procédés et compositions de prédiction de la réponse à un traitement avec un inhibiteur du tnf-α
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
WO2011146727A1 (fr) 2010-05-19 2011-11-24 Philip Bosch Méthodes de traitement de la cystite interstitielle
US8067375B2 (en) 2006-10-20 2011-11-29 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor
WO2011153477A2 (fr) 2010-06-03 2011-12-08 Abbott Biotechnology Ltd. Utilisations et compositions pour le traitement de l'hidrosadénite (hs)
WO2012007658A2 (fr) 2010-07-12 2012-01-19 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
EP2500037A2 (fr) 2005-05-16 2012-09-19 Abbott Biotechnology Ltd Utilisation d'un inhibiteur de TNF alpha pour traiter la polyarthrite érosive
WO2012129174A1 (fr) 2011-03-18 2012-09-27 Abbott Laboratories Systèmes, dispositifs et procédés pour assembler des dispositifs à injection automatique et des sous-ensembles leur correspondant
WO2012135524A1 (fr) 2011-03-29 2012-10-04 Abbott Laboratories Déploiement d'enveloppe amélioré dans des dispositifs d'injection automatique
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
WO2013016220A1 (fr) 2011-07-22 2013-01-31 Amgen Inc. Récepteur a de il-il-17 requis pour biologie il-17c
US8398977B2 (en) 2007-06-14 2013-03-19 Galactica Pharmaceuticals, Inc. Rage fusion proteins
US8436163B2 (en) 2000-05-04 2013-05-07 Avi Biopharma, Inc. Splice-region antisense composition and method
US8513393B2 (en) 2006-08-28 2013-08-20 Ares Trading S.A. Process for the purification of Fc-containing proteins
EP2666480A2 (fr) 2006-04-10 2013-11-27 Abbott Biotechnology Ltd Utilisations et compositions pour le traitement de la maladie de Crohn
EP2666479A2 (fr) 2006-04-10 2013-11-27 Abbott Biotechnology Ltd Utilisations et compositions pour le traitement de l'arthrite rhumatoïde juvénile
EP2679995A1 (fr) 2007-05-31 2014-01-01 AbbVie Inc. Biomarqueurs prédictifs de la réactivité aux inhibiteurs TNF-alfa dans des troubles auto-immuns
US8658379B2 (en) 2008-01-29 2014-02-25 University of Pittsburgh—of the Commonwealth System of Higher Education Follistatin-like protein-1 as a biomarker for sepsis
US8722615B2 (en) 2009-12-02 2014-05-13 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
US8741584B2 (en) 2010-08-05 2014-06-03 University of Pittsburgh—of the Commonwealth System of Higher Education Follistatin-like protein-1 as a biomarker for inflammatory disorders
EP2738179A1 (fr) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Purification d'anticorps
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
US9017287B2 (en) 2004-06-23 2015-04-28 Abbvie Biotechnology Ltd Automatic injection devices
WO2015153144A1 (fr) 2014-03-31 2015-10-08 Kirin-Amgen, Inc. Procédés de traitement du psoriasis des ongles et du cuir chevelu
WO2015198320A1 (fr) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Procédés de purification d'anticorps
EP3020428A1 (fr) 2011-04-21 2016-05-18 AbbVie Inc. Dispositif d'injection automatique portable pour l'administration contrôlée d'agents thérapeutiques
WO2016102328A1 (fr) 2014-12-22 2016-06-30 Ares Trading S.A. Composition pharmaceutique liquide
EP3078675A1 (fr) 2015-04-10 2016-10-12 Ares Trading S.A. Régime de dosage à induction pour le traitement des maladies liées au tnf alpha
US9486584B2 (en) 2006-06-30 2016-11-08 Abbvie Biotechnology Ltd. Automatic injection device
US9561328B2 (en) 2009-04-29 2017-02-07 Abbvie Biotechnology Ltd Automatic injection device
WO2017177179A1 (fr) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions et méthodes de traitement du cancer, de maladies inflammatoires et de maladies autoimmunes
EP3257866A1 (fr) 2016-06-17 2017-12-20 Academisch Medisch Centrum Anticorps anti-tnf modifiés et leur utilisation dans le traitement de la maladie intestinale inflammatoire
US9878102B2 (en) 2011-01-24 2018-01-30 Abbvie Biotechnology Ltd. Automatic injection devices having overmolded gripping surfaces
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
WO2018112240A1 (fr) 2016-12-14 2018-06-21 Progenity Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur du tnf
WO2018124948A1 (fr) 2016-12-30 2018-07-05 Закрытое Акционерное Общество "Биокад" Composition pharmaceutique aqueuse d'un anticorps monoclonal recombinant pour le facteur de nécrose tumorale (tnf) α
EP3360596A1 (fr) 2010-04-21 2018-08-15 AbbVie Biotechnology Ltd. Dispositif d'injection automatique vestimentaire pour l'administration contrôlée d'agents thérapeutiques
US10072085B2 (en) 2010-01-15 2018-09-11 Kirin-Amgen, Inc. Method of treating psoriasis using an IL-17 receptor antibody formulation
US10258689B2 (en) 2011-06-03 2019-04-16 Lg Chem, Ltd. Stable liquid formulation of etanercept
WO2019246313A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur du tnf
WO2020010118A1 (fr) 2018-07-03 2020-01-09 Novartis Inflammasome Research, Inc. Méthodes de traitement ou de sélection d'un traitement pour un sujet résistant à un inhibiteur de tnf à l'aide d'un antagoniste de nlrp3
US10888619B2 (en) 2011-10-18 2021-01-12 Coherus Biosciences, Inc. Stable aqueous etanercept composition
US10927435B2 (en) 2011-10-11 2021-02-23 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same
US10947306B2 (en) 2012-09-11 2021-03-16 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
WO2021109913A1 (fr) * 2019-12-05 2021-06-10 沣潮医药科技（上海）有限公司 Immunoadhésine dimère antipaludique, composition pharmaceutique et utilisation associée
US11098127B2 (en) 2010-01-08 2021-08-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
US11319375B2 (en) 2018-08-29 2022-05-03 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis
WO2022123293A1 (fr) 2020-12-09 2022-06-16 에이치케이이노엔 주식회사 ANTICORPS ANTI-OX40L, ANTICORPS BISPÉCIFIQUE ANTI-OX40L/ANTI-TNFα ET LEURS UTILISATIONS
US11498969B2 (en) 2019-01-31 2022-11-15 Sanofi Biotechnology Compositions and methods for treating juvenile idiopathic arthritis

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP2006512900A (ja) * 2002-08-16 2006-04-20 ワイス Ｒａｇｅ関連疾患の治療用組成物及び方法
CN1694958A (zh) * 2002-09-13 2005-11-09 昆士兰大学 以密码子翻译效率为基础的基因表达系统
AU2004279742A1 (en) * 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
JP2010501622A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ−融合タンパク質の精製法
KR101525919B1 (ko) * 2012-05-11 2015-06-03 가톨릭대학교 산학협력단 자가면역 질환 예방 및 치료를 위한 ｔｎｆｒ２를 기반으로 하는 이중 항체

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2485553A1 (fr) * 1989-09-05 1991-03-21 Immunex Corporation Recepteurs .alpha. et .beta. de facteur de necrose tumorale
ATE190629T1 (de) * 1991-01-18 2000-04-15 Amgen Inc Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
CA2145192A1 (fr) * 1992-09-22 1994-03-31 Gail Underiner Nouveaux composes renfermant de l'epoxyde

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Journal of Clinical Investigation, Vol. 91, issued April 1993, "The Power of Negative Thinking", pages 1265-1266, see entire document. *
Molecular Immunology, Vol. 28, No. 9, issued 1991, HOOGENBOOM et al., "Construction and Expression of Antibody-Tumor Necrosis Factor Fusion Proteins", pages 1027-1037, see entire document. *
Science, Vol. 24, issued 25 May 1990, SMITH et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins", pages 1019-1023, see entire document. *
See also references of EP0620739A4 *
The Lancet, issued 29 July 1989, BRENNAN et al., "Inhibitory Effect of TNFalpha Antibodies on Synovial Cell Interleukin-1 Production in Rheumatoid Arthritis", pages 244-247, see entire document. *
The New England Journal of Medicine, Vol. 322, No. 18, issued 03 May 1990, HARRIS et al., "Mechanisms of Disease: Rheumatoid Arthritis", pages 1277-1289, see entire document. *

Cited By (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440693B1 (en) 1989-04-21 2002-08-27 Rudolf Hauptmann TNF receptors, TNF binding proteins and DNAS coding for them
US6417158B1 (en) * 1989-04-21 2002-07-09 Amgen, Inc. Method of ameliorating the harmful effects of TNF using a polypeptide having the ability to bind to TNF
US7238776B2 (en) 1989-04-21 2007-07-03 Amgen Inc. TNF binding proteins
US7282483B2 (en) 1989-04-21 2007-10-16 Amgen Inc. Method of ameliorating the harmful effects of TNF using a polypeptide having the ability to bind to TNF
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6294352B1 (en) * 1989-04-21 2001-09-25 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6271346B1 (en) 1989-04-21 2001-08-07 Amgen Inc. TNF Receptors, TNF binding proteins and DNAs coding for them
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US6541620B1 (en) 1989-07-18 2003-04-01 Angen Inc. Nucleic acids encoding TNF inhibitor and method of production
EP0670730A4 (fr) * 1992-03-30 1997-02-26 Immunex Corp Proteines de fusion comprenant un recepteur de facteur de necrose tumorale.
EP0670730A1 (fr) * 1992-03-30 1995-09-13 Immunex Corporation Proteines de fusion comprenant un recepteur de facteur de necrose tumorale
US7846442B2 (en) 1992-10-08 2010-12-07 The Mathilda And Terence Kennedy Institute Of Rheumatology Trust Methods of treating rheumatoid arthritis with an anti-TNF-alpha antibodies and methotrexate
WO1996003141A1 (fr) * 1994-07-22 1996-02-08 F. Hoffmann-La Roche Ag Compositions pharmaceutiques comprenant une proteine chimere liant le facteur de necrose tumorale
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
WO1996023888A1 (fr) * 1995-02-03 1996-08-08 G.D. Searle & Co. NOUVEAUX LIGANDS SE FIXANT A c-MPL
EP0812208A1 (fr) * 1995-03-01 1997-12-17 YEDA RESEARCH AND DEVELOPMENT CO., Ltd. Compositions pharmaceutiques destinees a la liberation regulee de recepteurs solubles
EP0812208A4 (fr) * 1995-03-01 2004-06-30 Yeda Res Anddevelopment Co Ltd Compositions pharmaceutiques destinees a la liberation regulee de recepteurs solubles
EP1609853B2 (fr) † 1995-06-06 2020-01-22 F.Hoffmann-La Roche Ag Procéde de regulation de la sialylation de proteines produites par une culture de cellules de mammiferes
US7666416B2 (en) 1995-06-06 2010-02-23 Genentech, Inc. Mammalian cell culture process
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
EP1609853A1 (fr) * 1995-06-06 2005-12-28 F.Hoffmann-La Roche Ag Procéde de regulation de la sialylation de proteines produites par une culture de cellules de mammiferes
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
WO1996039488A1 (fr) * 1995-06-06 1996-12-12 Genentech, Inc. Procede de regulation de la sialylation de proteines produites par une culture de cellules de mammiferes
WO1997003686A1 (fr) * 1995-07-14 1997-02-06 Applied Research Systems Recepteur de tnf et hormone steroïdienne en therapie combinee
US6225300B1 (en) 1995-07-14 2001-05-01 Applied Research Systems Ars Holding Nv TNF receptor and steroid hormone in a combined therapy
US7012060B1 (en) 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
US8080254B2 (en) 1995-11-22 2011-12-20 Amgen, Inc. OB fusion protein compositions and methods
US7718400B2 (en) 1995-11-22 2010-05-18 Amylin Pharmaceuticals, Inc. Methods of increasing lean tissue mass using OB protein compositions
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US7208577B2 (en) 1995-11-22 2007-04-24 Amgen, Inc. Methods of increasing lean tissue mass using OB protein compositions
US7112659B2 (en) 1995-11-22 2006-09-26 Amgen, Inc. OB fusion protein compositions and methods
EP2305713A1 (fr) 1996-02-09 2011-04-06 Abbott Biotechnology Ltd Anticorps humains se fixant au facteur nécrosant des tumeurs de type alpha
EP2305712A1 (fr) 1996-02-09 2011-04-06 Abbott Biotechnology Ltd Anticorps humains se fixant au facteur necrosant des tumeurs de type alpha
EP2930186A1 (fr) 1996-02-09 2015-10-14 AbbVie Biotechnology Ltd Anticorps humains qui se lient au tnfalpha
EP2933267A1 (fr) 1996-02-09 2015-10-21 AbbVie Biotechnology Ltd Anticorps humains qui se lient au tnf alpha humain
EP2357200A1 (fr) 1996-02-09 2011-08-17 Abbott Biotechnology Ltd Anticorps humains se fixant au facteur necrosant des tumeurs de type alpha
EP2397494A1 (fr) 1996-02-09 2011-12-21 Abbott Biotechnology Ltd Anticorps humains qui se lient au TNFalpha
EP2930187A1 (fr) 1996-02-09 2015-10-14 AbbVie Biotechnology Ltd Anticorps humains qui se lient au tnf alpha humain
EP2930185A1 (fr) 1996-02-09 2015-10-14 AbbVie Biotechnology Ltd Anticorps humains qui se lient au tnfalpha
WO1997041895A3 (fr) * 1996-05-08 1998-03-12 Hoffmann La Roche TRAITEMENT DE L'ASTHME PAR TNFR-Ig
WO1997041895A2 (fr) * 1996-05-08 1997-11-13 F. Hoffmann-La Roche Ag TRAITEMENT DE L'ASTHME PAR TNFR-Ig
US7732587B2 (en) 1996-07-09 2010-06-08 Amgen Inc. Nucleic acids encoding truncated soluble tumor necrosis factor
US7838489B2 (en) 1996-08-01 2010-11-23 The Mathilda And Terence Kennedy Institute Of Rheumatology Trust Methods of treating rheumatoid arthritis with p75 TNF-alpha receptor and methotrexate
US8383120B2 (en) 1996-08-01 2013-02-26 The Mathilda And Terence Kennedy Institute Of Rheumatology Trust Concomitant treatment of rheumatoid arthritis with anti-TNF-alpha antibodies and methotrexate
US8298537B2 (en) 1996-08-01 2012-10-30 The Mathilda And Terence Kennedy Institute Of Rheumatology Trust Concomitant treatment of rheumatoid arthritis with anti-TNF-α antibodies and methotrexate
EP1352656A3 (fr) * 1996-12-06 2004-02-04 Amgen Inc. Thérapie combinatoire utilisant une protèine de liaison du facteur de nécrose tumorale (TNF) dans le traitement de maladies induites par le TNF
EP1352656A2 (fr) * 1996-12-06 2003-10-15 Amgen Inc. Thérapie combinatoire utilisant une protèine de liaison du facteur de nécrose tumorale (TNF) dans le traitement de maladies induites par le TNF
US6306820B1 (en) 1996-12-06 2001-10-23 Amgen Inc. Combination therapy using a TNF binding protein for treating TNF-mediated diseases
WO1998024463A3 (fr) * 1996-12-06 1998-07-16 Amgen Inc Therapie combinatoire utilisant une proteine de liaison du facteur de necrose tumorale (tnf) dans le traitement de maladies induites par le tnf
WO1998024463A2 (fr) * 1996-12-06 1998-06-11 Amgen Inc. Therapie combinatoire utilisant une proteine de liaison du facteur de necrose tumorale (tnf) dans le traitement de maladies induites par le tnf
US6733753B2 (en) 1997-02-10 2004-05-11 Amgen Inc. Composition and method for treating inflammatory diseases
EP1170017A1 (fr) * 1997-05-12 2002-01-09 The Kennedy Institute Of Rheumatology Utilisation du facteur de nécrose tumorale alpha (TNF-alpha) et du facteur de croissance des cellules endothéliales (VEGF) pour la préparation d'une composition thérapeutique
WO1998051344A1 (fr) * 1997-05-12 1998-11-19 The Kennedy Institute Of Rheumatology Suppression therapeutique du facteur de necrose tumorale alpha et du facteur de croissance des cellules endotheliales vasculaires
WO1999003999A1 (fr) * 1997-07-17 1999-01-28 The Regents Of The University Of Michigan Procedes et compositions servant a inhiber la reaction proinflammatoire
EP1097165A1 (fr) * 1998-07-13 2001-05-09 Parkash S. Gill Nouveaux inhibiteurs de l'angiogenese et de la croissance tumorale
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
WO2000025745A2 (fr) * 1998-11-05 2000-05-11 Omeros Medical Systems, Inc. Solution d'irrigation et methode pour l'inhibition de la douleur et de l'inflammation
WO2000025745A3 (fr) * 1998-11-05 2000-08-24 Omeros Med Sys Inc Solution d'irrigation et methode pour l'inhibition de la douleur et de l'inflammation
US8709759B2 (en) 1998-12-17 2014-04-29 Biogen Idec Ma Inc. Method for increasing expression of active tumor necrosis factor receptor family member-Ig fusion proteins
SG123531A1 (en) * 1998-12-17 2006-07-26 Biogen Idec Inc A method for the high level expression of active lymphotoxin-beta receptor immunoglobulin chimeric proteins and their purification
US8283138B2 (en) 1998-12-17 2012-10-09 Biogen Idec Ma Inc. Method for the high level expression of active tumor necrosis receptor family member immunoglobulin fusion proteins
US6608044B1 (en) * 1998-12-30 2003-08-19 Applied Research Systems Ars Holding N.V. Inhibition of TNF activity
WO2000040225A2 (fr) * 1998-12-30 2000-07-13 Applied Research Systems Ars Holding N.V. Inhibition de l'activite du tnf
WO2000040225A3 (fr) * 1998-12-30 2000-09-21 Applied Research Systems Inhibition de l'activite du tnf
CZ302866B6 (cs) * 1999-01-22 2011-12-21 Laboratoires Serono Sa Farmaceutický prostredek
WO2000043031A1 (fr) * 1999-01-22 2000-07-27 Applied Research Systems Ars Holding N.V. Antagonistes de facteurs de necroses tumorales et utilisation de ceux-ci dans les cas d'endometriose
EP1022027A1 (fr) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Antagonistes du TNF (Tumor necrosis factor) et leurs utilisations contre l'endometriose
WO2000059530A1 (fr) * 1999-04-02 2000-10-12 Immunex Corporation Utilisation d'un recepteur du facteur de necrose tumorale soluble dans le traitement de l'insuffisance cardiaque
US6537540B1 (en) 1999-05-28 2003-03-25 Targeted Genetics Corporation Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
WO2000073481A1 (fr) * 1999-05-28 2000-12-07 Targeted Genetics Corporation Techniques et compositions permettant d'abaisser le niveau de facteur de necrose tumorale (tnf) dans les troubles associes au tnf
AU2005244527B2 (en) * 1999-05-28 2008-09-18 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (TNF) in the TNF-associated disorders
AU2005244527C1 (en) * 1999-05-28 2009-02-05 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (TNF) in the TNF-associated disorders
EP1939300A1 (fr) * 1999-05-28 2008-07-02 Targeted Genetics Corporation Procédés et compositions pour diminuer le niveau de facteur de nécrose de tumeur (TNF) pour des troubles associés au TNF
US7320796B2 (en) 1999-07-09 2008-01-22 Amgen Inc. Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
EP1797869A3 (fr) * 1999-07-21 2008-07-23 Omeros Corporation Solutions et procédés pour l'inhibition d'inflammations douloureuses et de détériorations du cartilage
EP2322226A3 (fr) * 1999-07-21 2011-08-17 Omeros Corporation Solutions et procédés pour l'inhibition de la douleur, la inflammation et la degradation du cartilage
US7544519B2 (en) 1999-08-04 2009-06-09 Amgen Inc. Fhm a novel member of the TNF ligand supergene family: materials and methods for interaction modulators
US7118863B2 (en) 1999-08-04 2006-10-10 Amgen, Inc. Methods for detecting NTR3 nucleic acids by hybridization
WO2001038526A1 (fr) * 1999-11-23 2001-05-31 Glaxo Group Limited Récepteur de tnf humain
US8436163B2 (en) 2000-05-04 2013-05-07 Avi Biopharma, Inc. Splice-region antisense composition and method
US8895722B2 (en) 2000-05-04 2014-11-25 Sarepta Therapeutics, Inc. Splice-region antisense composition and method
US10533174B2 (en) 2000-05-04 2020-01-14 Sarepta Therapeutics, Inc. Splice-region antisense composition and method
US9416361B2 (en) 2000-05-04 2016-08-16 Sarepta Therapeutics, Inc. Splice-region antisense composition and method
EP2940044A1 (fr) 2001-06-08 2015-11-04 AbbVie Biotechnology Ltd Procédés d'administration d'anticorps anti-tnfalpha
EP2364731A2 (fr) 2001-06-08 2011-09-14 Abbott Biotechnology Ltd Méthodes d'administration d'anticorps anti-TNFalpha
WO2002100330A2 (fr) 2001-06-08 2002-12-19 Abbott Biotechnology Ltd Methodes d'administration d'anticorps anti-tnf$g(a)
EP3190124A1 (fr) 2001-06-08 2017-07-12 AbbVie Biotechnology Ltd Adalimumab pour l'utilisation dans la thérapie de l'arthrite rhumatoïde
EP2359855A2 (fr) 2001-06-08 2011-08-24 Abbott Biotechnology Ltd Procédés d'administration d'anticorps anti-TNFalpha
EP2324851A1 (fr) 2001-06-08 2011-05-25 Abbott Biotechnology Ltd Methodes d'administration d'anticorps anti-TNFalpha
US7670602B2 (en) 2001-07-26 2010-03-02 Medexgen Co., Ltd Concatameric immunoadhesion molecule
US8372961B2 (en) 2001-07-26 2013-02-12 Medexgen Co., Ltd. Polynucleotides encoding concatameric immunoadhesion molecules
US7229962B2 (en) 2001-07-26 2007-06-12 Medexgen Co., Ltd. Tetravalent etanercept
EP2196218A2 (fr) 2002-04-26 2010-06-16 Abbott Biotechnology Ltd Utilisation d'anticorps anti-TNFalpha et d'un autre médicament
EP2347766A1 (fr) 2002-04-26 2011-07-27 Abbott Biotechnology Ltd Utilisation d'anticorps anti-TNF dollar g(a) et d'un autre produit pharmaceutique
EP1944322A2 (fr) 2002-07-19 2008-07-16 Abbott Biotechnology Ltd. Traitement des troubles associés au TND alpha
EP2298810A2 (fr) 2002-07-19 2011-03-23 Abbott Biotechnology Ltd Traitement des troubles associés au TND alpha
EP2371859A2 (fr) 2002-07-19 2011-10-05 Abbott Biotechnology Ltd Traitement des troubles associés au TND alpha
EP2942359A1 (fr) 2002-07-19 2015-11-11 AbbVie Biotechnology Ltd Traitement des troubles associés au TND alpha
EP2336182A1 (fr) 2002-07-19 2011-06-22 Abbott Biotechnology Ltd Traitement des troubles associés au TND alpha
WO2004037205A2 (fr) 2002-10-24 2004-05-06 Abbott Biotechnology Ltd. THERAPIES FAIBLEMENT DOSEES POUR TRAITER DES TROUBLES POUR LESQUELS L'ACTIVITE DES FACTEURS DE NECROSE TUMORALE α EST PREJUDICIABLE
EP2332565A1 (fr) 2002-10-24 2011-06-15 Abbott Biotechnology Ltd. Thérapies faiblement dosées pour traiter des troubles pour lesquels l'activité des facteurs de nécrose tumorale alpha est préjudiciable
EP2295071A1 (fr) 2002-10-24 2011-03-16 Abbott Biotechnology Ltd Thérapies faiblement dosées pour traiter des troubles pour lesquels l'activité des facteurs de nécrose tumorale alpha est préjudiciable
US8937045B2 (en) 2003-02-28 2015-01-20 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding proteins
US9512215B2 (en) 2003-02-28 2016-12-06 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding proteins
EA009079B1 (ru) * 2003-02-28 2007-10-26 Арес Трейдинг С.А. Жидкие составы фактор некроза опухоли-связывающих белков
WO2004075918A1 (fr) * 2003-02-28 2004-09-10 Ares Trading S.A. Preparations liquides de proteines de liaison au facteur de necrose tumorale
EP2335732A2 (fr) 2004-04-09 2011-06-22 Abbott Biotechnology Ltd RÉGIME POSOLOGIQUE À VARIABLES MULTIPLES DESTINÉ A TRAITER DES MALADIES ASSOCIÉES À TNFalpha
EP2335731A2 (fr) 2004-04-09 2011-06-22 Abbott Biotechnology Ltd Régime posologique à variables multiples destiné à traiter des troubles associés à TNF-alpha
WO2005110452A2 (fr) 2004-04-09 2005-11-24 Abbott Biotechnology Ltd. Regime posologique a variables multiples destine a traiter des troubles associes a tnf?
EP2338516A2 (fr) 2004-04-09 2011-06-29 Abbott Biotechnology Ltd Régimes posologiques multiples et variables pour traiter les troubles liés au TNF-alpha
US9764090B2 (en) 2004-06-23 2017-09-19 Abbvie Biotechnology Ltd Relating to automatic injection devices
US9017287B2 (en) 2004-06-23 2015-04-28 Abbvie Biotechnology Ltd Automatic injection devices
WO2006053301A3 (fr) * 2004-11-12 2007-04-05 Xencor Inc Variants fc presentant une liaison modifiee au fcrn
WO2006105344A2 (fr) * 2005-03-31 2006-10-05 Targeted Genetics Corporation Procedes d'abaissement de niveau de facteur tnf dans les troubles associes a ce facteur
WO2006105344A3 (fr) * 2005-03-31 2007-01-11 Targeted Genetics Corp Procedes d'abaissement de niveau de facteur tnf dans les troubles associes a ce facteur
EP2500037A2 (fr) 2005-05-16 2012-09-19 Abbott Biotechnology Ltd Utilisation d'un inhibiteur de TNF alpha pour traiter la polyarthrite érosive
WO2007024705A2 (fr) 2005-08-19 2007-03-01 Abbott Biotechnology Ltd. Procede de traitement de la depression au moyen d'un anticorps anti-tnf-alpha
EP2357479A1 (fr) 2005-11-01 2011-08-17 Abbott Biotechnology Ltd Procédés et compositions pour le diagnostic de spondylite ankylosante au moyen de biomarqueurs
WO2007089303A2 (fr) 2005-11-01 2007-08-09 Abbott Biotechnology Ltd. Méthodes et compositions de diagnostic de la spondylarthrite ankylosante à l'aide de biomarqueurs
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
US7972599B2 (en) 2006-03-20 2011-07-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Immunomodulation of inflammatory conditions utilizing Follistatin-like protein-1 and agents that bind thereto
US8334274B2 (en) 2006-03-20 2012-12-18 University Of Pittsburg—Of The Commonwealth of Higher Education Immunomodulation of inflammatory conditions utilizing Follistatin-like Protein-1 and agents that bind thereto
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
EP2738178A1 (fr) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Purification d'anticorps
EP2738179A1 (fr) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Purification d'anticorps
EP3088410A2 (fr) 2006-04-05 2016-11-02 AbbVie Biotechnology Ltd Purification d'anticorps
WO2008063213A2 (fr) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
EP2666472A2 (fr) 2006-04-10 2013-11-27 Abbott Biotechnology Ltd Utilisations et compositions pour le traitement de l'arthrite psoriasique
EP2708242A2 (fr) 2006-04-10 2014-03-19 Abbott Biotechnology Ltd Utilisations et compositions pour le traitement de la spondylarthrite ankylosante
EP2703010A2 (fr) 2006-04-10 2014-03-05 Abbott Biotechnology Ltd. Utilisations et compositions pour le traitement de l'arthrite rhumatoïde
EP2666480A2 (fr) 2006-04-10 2013-11-27 Abbott Biotechnology Ltd Utilisations et compositions pour le traitement de la maladie de Crohn
EP2666479A2 (fr) 2006-04-10 2013-11-27 Abbott Biotechnology Ltd Utilisations et compositions pour le traitement de l'arthrite rhumatoïde juvénile
EP2666478A2 (fr) 2006-04-10 2013-11-27 Abbott Biotechnology Ltd Utilisations et compositions pour le traitement du psoriasis
US9486584B2 (en) 2006-06-30 2016-11-08 Abbvie Biotechnology Ltd. Automatic injection device
US8513393B2 (en) 2006-08-28 2013-08-20 Ares Trading S.A. Process for the purification of Fc-containing proteins
EA017733B1 (ru) * 2006-08-28 2013-02-28 Арес Трейдинг С.А. СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
WO2008025747A1 (fr) * 2006-08-28 2008-03-06 Ares Trading S.A. Procédé de purification de protéines fc-hybrides
EP3165539A1 (fr) 2006-10-02 2017-05-10 Kirin-Amgen, Inc. Protéines se liant à des antigènes a du récepteur il-17
US11858999B2 (en) 2006-10-02 2024-01-02 Amgen K-A, Inc. IL-17 receptor A antigen binding proteins
US11180564B2 (en) 2006-10-02 2021-11-23 Amgen K-A, Inc. IL-17 Receptor A antigen binding proteins
US10208122B2 (en) 2006-10-02 2019-02-19 Amgen K-A, Inc. IL-17 receptor A antigen binding proteins
WO2008054603A2 (fr) 2006-10-02 2008-05-08 Amgen Inc. Protéines de liaison à l'antigène du récepteur a de l'il-17
US8067375B2 (en) 2006-10-20 2011-11-29 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor
WO2008051306A1 (fr) * 2006-10-20 2008-05-02 Ercole Biotech, Inc. Récepteurs de tnf solubles et leur utilisation pour le traitement de maladies
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP2679995A1 (fr) 2007-05-31 2014-01-01 AbbVie Inc. Biomarqueurs prédictifs de la réactivité aux inhibiteurs TNF-alfa dans des troubles auto-immuns
EP2679996A1 (fr) 2007-05-31 2014-01-01 AbbVie Inc. Biomarqueurs prédictifs de la réactivité aux inhibiteurs TNF-alfa dans des troubles auto-immuns
WO2008154543A2 (fr) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Procédés de traitement de l'arthrite idiopathique juvénile
US9066927B2 (en) 2007-06-14 2015-06-30 Galactica Pharmaceuticals, Inc. Methods of treatment using rage fusion proteins
US8398977B2 (en) 2007-06-14 2013-03-19 Galactica Pharmaceuticals, Inc. Rage fusion proteins
US9399668B2 (en) 2007-06-14 2016-07-26 Galactica Pharmaceuticals, Inc. Nucleic acids encoding rage fusion proteins
EP2072527A1 (fr) 2007-12-21 2009-06-24 Altonabiotec AG Procédé et système pour fournir des services de communications sur un terminal mobile, et terminal mobile
US8658379B2 (en) 2008-01-29 2014-02-25 University of Pittsburgh—of the Commonwealth System of Higher Education Follistatin-like protein-1 as a biomarker for sepsis
WO2010018444A3 (fr) * 2008-08-12 2010-05-14 Avesthagen Limited Vecteur d'expression et son procédé
WO2010018444A2 (fr) * 2008-08-12 2010-02-18 Avesthagen Limited Vecteur d'expression et son procédé
WO2010077722A1 (fr) 2008-12-30 2010-07-08 Centocor Ortho Biotech Inc. Marqueurs sériques prédisant la réponse clinique à des anticorps anti-tnf chez les patients souffrant de spondylarthrite ankylosante
US9561328B2 (en) 2009-04-29 2017-02-07 Abbvie Biotechnology Ltd Automatic injection device
WO2011046958A1 (fr) 2009-10-12 2011-04-21 Amgen Inc. Utilisation des proteines se liant a un antigene du recepteur a de l'il-17
US8722615B2 (en) 2009-12-02 2014-05-13 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
WO2011075578A1 (fr) 2009-12-16 2011-06-23 Philip Bosch Procédés de traitement de la cystite interstitielle
US11098127B2 (en) 2010-01-08 2021-08-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
US11505612B2 (en) 2010-01-15 2022-11-22 Amgen K-A, Inc. Method of treating diseases using an IL-17 receptor antibody formulation
US10808033B2 (en) 2010-01-15 2020-10-20 Amgen K-A, Inc. IL-17 receptor antibody formulation
US10072085B2 (en) 2010-01-15 2018-09-11 Kirin-Amgen, Inc. Method of treating psoriasis using an IL-17 receptor antibody formulation
WO2011097301A2 (fr) 2010-02-02 2011-08-11 Abbott Biotechnology Ltd. Procédés et compositions de prédiction de la réponse à un traitement avec un inhibiteur du tnf-α
EP3360596A1 (fr) 2010-04-21 2018-08-15 AbbVie Biotechnology Ltd. Dispositif d'injection automatique vestimentaire pour l'administration contrôlée d'agents thérapeutiques
WO2011146727A1 (fr) 2010-05-19 2011-11-24 Philip Bosch Méthodes de traitement de la cystite interstitielle
WO2011153477A2 (fr) 2010-06-03 2011-12-08 Abbott Biotechnology Ltd. Utilisations et compositions pour le traitement de l'hidrosadénite (hs)
WO2012007658A2 (fr) 2010-07-12 2012-01-19 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
US8741584B2 (en) 2010-08-05 2014-06-03 University of Pittsburgh—of the Commonwealth System of Higher Education Follistatin-like protein-1 as a biomarker for inflammatory disorders
US11565048B2 (en) 2011-01-24 2023-01-31 Abbvie Biotechnology Ltd. Automatic injection devices having overmolded gripping surfaces
US9878102B2 (en) 2011-01-24 2018-01-30 Abbvie Biotechnology Ltd. Automatic injection devices having overmolded gripping surfaces
WO2012129174A1 (fr) 2011-03-18 2012-09-27 Abbott Laboratories Systèmes, dispositifs et procédés pour assembler des dispositifs à injection automatique et des sous-ensembles leur correspondant
WO2012135524A1 (fr) 2011-03-29 2012-10-04 Abbott Laboratories Déploiement d'enveloppe amélioré dans des dispositifs d'injection automatique
EP3020428A1 (fr) 2011-04-21 2016-05-18 AbbVie Inc. Dispositif d'injection automatique portable pour l'administration contrôlée d'agents thérapeutiques
US9956345B2 (en) 2011-04-21 2018-05-01 Abbvie Inc. Wearable automatic injection device for controlled administration of therapeutic agents
US10258689B2 (en) 2011-06-03 2019-04-16 Lg Chem, Ltd. Stable liquid formulation of etanercept
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
WO2013016220A1 (fr) 2011-07-22 2013-01-31 Amgen Inc. Récepteur a de il-il-17 requis pour biologie il-17c
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
US10927435B2 (en) 2011-10-11 2021-02-23 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same
US10987405B2 (en) 2011-10-18 2021-04-27 Coherus Biosciences, Inc. Method of reducing formation of etanercept aggregates or fragments
US10980884B2 (en) 2011-10-18 2021-04-20 Coherus Biosciences, Inc. Stable aqueous etanercept composition
US10980885B2 (en) 2011-10-18 2021-04-20 Coherus Biosciences, Inc. Method of reducing formation of etanercept aggregates or fragments
US10888619B2 (en) 2011-10-18 2021-01-12 Coherus Biosciences, Inc. Stable aqueous etanercept composition
US10954293B2 (en) 2012-09-11 2021-03-23 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
US10954294B2 (en) 2012-09-11 2021-03-23 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
US11001627B2 (en) 2012-09-11 2021-05-11 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
US10954295B2 (en) 2012-09-11 2021-03-23 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
US10947306B2 (en) 2012-09-11 2021-03-16 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
WO2015153144A1 (fr) 2014-03-31 2015-10-08 Kirin-Amgen, Inc. Procédés de traitement du psoriasis des ongles et du cuir chevelu
WO2015198320A1 (fr) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Procédés de purification d'anticorps
US10959939B2 (en) 2014-12-22 2021-03-30 Ares Trading S.A. Liquid pharmaceutical composition of etanercept with lysine and proline
WO2016102328A1 (fr) 2014-12-22 2016-06-30 Ares Trading S.A. Composition pharmaceutique liquide
EP3078676A1 (fr) 2015-04-10 2016-10-12 Ares Trading S.A. Régime de dosage à induction pour le traitement des maladies liées au tnf alpha
EP3078675A1 (fr) 2015-04-10 2016-10-12 Ares Trading S.A. Régime de dosage à induction pour le traitement des maladies liées au tnf alpha
WO2016162537A1 (fr) 2015-04-10 2016-10-13 Ares Trading S.A Schéma posologique d'induction
WO2017177179A1 (fr) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions et méthodes de traitement du cancer, de maladies inflammatoires et de maladies autoimmunes
EP3257866A1 (fr) 2016-06-17 2017-12-20 Academisch Medisch Centrum Anticorps anti-tnf modifiés et leur utilisation dans le traitement de la maladie intestinale inflammatoire
WO2018112240A1 (fr) 2016-12-14 2018-06-21 Progenity Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur du tnf
WO2018124948A1 (fr) 2016-12-30 2018-07-05 Закрытое Акционерное Общество "Биокад" Composition pharmaceutique aqueuse d'un anticorps monoclonal recombinant pour le facteur de nécrose tumorale (tnf) α
WO2019246313A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur du tnf
WO2020010118A1 (fr) 2018-07-03 2020-01-09 Novartis Inflammasome Research, Inc. Méthodes de traitement ou de sélection d'un traitement pour un sujet résistant à un inhibiteur de tnf à l'aide d'un antagoniste de nlrp3
US11319375B2 (en) 2018-08-29 2022-05-03 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis
US11498969B2 (en) 2019-01-31 2022-11-15 Sanofi Biotechnology Compositions and methods for treating juvenile idiopathic arthritis
WO2021109913A1 (fr) * 2019-12-05 2021-06-10 沣潮医药科技（上海）有限公司 Immunoadhésine dimère antipaludique, composition pharmaceutique et utilisation associée
WO2022123293A1 (fr) 2020-12-09 2022-06-16 에이치케이이노엔 주식회사 ANTICORPS ANTI-OX40L, ANTICORPS BISPÉCIFIQUE ANTI-OX40L/ANTI-TNFα ET LEURS UTILISATIONS

Also Published As

Publication number Publication date
CA2123593C (fr) 2000-03-14
AU670125B2 (en) 1996-07-04
NZ256293A (en) 1997-06-24
NO941780D0 (no) 1994-05-11
EP0620739A4 (en) 1997-01-15
AU4920993A (en) 1994-04-12
NO941780L (no) 1994-07-15
JPH07504203A (ja) 1995-05-11
KR100232688B1 (ko) 1999-12-01
CA2123593A1 (fr) 1994-03-31
EP0620739A1 (fr) 1994-10-26

Similar Documents

Publication Publication Date Title
AU670125B2 (en) Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5605690A (en) Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US6201105B1 (en) Tumor necrosis factor receptor polypeptides recombinant P75 (Type II)
EP0418014B1 (fr) Récepteurs pour le facteur de nécrose de tumeur alpha et beta
CA2065346C (fr) Recepteurs .alpha. et .beta. de facteur de necrose tumorale
US5945397A (en) Purified p75 (type II) tumor necrosis factor receptor polypeptides
EP0460846B1 (fr) Récepteurs de type II de l'interleukine 1
AU646695B2 (en) Isolated viral protein cytokine antagonists
AU647566B2 (en) Leukemia inhibitory factor receptors
IE83679B1 (en) Type II interleukin-1 receptors
NZ251820A (en) Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
IE911108A1 (en) Isolated Viral Protein Cytokine Antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA FI JP KR NO NZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2123593

Country of ref document: CA

Ref document number: 1993921562

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019940701636

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 256293

Country of ref document: NZ

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1993921562

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993921562

Country of ref document: EP